FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3132389716> ?p ?o ?g. }

• W3132389716 endingPage "1546" @default.
• W3132389716 startingPage "1537" @default.
• W3132389716 abstract "Adversely prognostic hypercellular and hyperperfused regions of glioblastoma (GBM) predict progression-free survival, and are a novel target for dose-intensified chemoradiation (chemoRT) recently implemented in a phase II clinical trial. As a secondary aim, we hypothesized that dose-intensified chemoRT would induce greater mid-treatment response of hypercellular/hyperperfused tumor regions vs standard chemoradiation, and that early response would improve overall survival (OS).Forty-nine patients with newly diagnosed GBM underwent prospective, multiparametric high b value diffusion-weighted MRI (DW-MRI) and perfusion dynamic contrast-enhanced MRI (DCE-MRI) pre-RT and 3-4 weeks into RT. The hypercellular tumor volume (TVHCV, mean contralateral normal brain + 2SD) and hyperperfused tumor volume (TVCBV, contralateral normal frontal gray matter + 1SD) were generated using automated thresholding. Twenty-six patients were enrolled on a dose-escalation trial targeting TVHCV/TVCBV with 75 Gy in 30 fractions, and 23 non-trial patients comprised the control group. OS was estimated using the Kaplan-Meier method and compared using the log-rank test. The effect of TVHCV/TVCBV and Gd-enhanced tumor volume on OS was assessed using multivariable Cox proportional-hazard regression.Most patients had gross total (47%) or subtotal resection (37%), 25% were MGMT-methylated. Patients treated on the dose-escalation trial had significantly greater reduction in TVHCV/TVCBV (41% reduction, IQR 17%-75%) vs non-trial patients (6% reduction, IQR 6%-22%, P = .002). An increase in TVHCV/TVCBV during chemoRT was associated with worse OS (adjusted hazard ratio [aHR] 1.2, 95%CI 1.0-1.4, P = .02), while pre-treatment tumor volumes (P > .5) and changes in Gd-enhanced volume (P = .9) were not.Multiparametric MRI permits identification of therapeutic resistance during chemoRT and supports adaptive strategies in future trials." @default.
• W3132389716 created "2021-03-01" @default.
• W3132389716 creator A5000050947 @default.
• W3132389716 creator A5001497458 @default.
• W3132389716 creator A5014871240 @default.
• W3132389716 creator A5020712237 @default.
• W3132389716 creator A5021609838 @default.
• W3132389716 creator A5046132413 @default.
• W3132389716 creator A5046406895 @default.
• W3132389716 creator A5060316016 @default.
• W3132389716 creator A5070289110 @default.
• W3132389716 date "2021-02-18" @default.
• W3132389716 modified "2023-10-17" @default.
• W3132389716 title "Response assessment during chemoradiation using a hypercellular/hyperperfused imaging phenotype predicts survival in patients with newly diagnosed glioblastoma" @default.
• W3132389716 cites W1870281475 @default.
• W3132389716 cites W1970900709 @default.
• W3132389716 cites W2039335013 @default.
• W3132389716 cites W2041481362 @default.
• W3132389716 cites W2063999920 @default.
• W3132389716 cites W2076981660 @default.
• W3132389716 cites W2096287682 @default.
• W3132389716 cites W2108090165 @default.
• W3132389716 cites W2122980388 @default.
• W3132389716 cites W2125354863 @default.
• W3132389716 cites W2136291686 @default.
• W3132389716 cites W2143987763 @default.
• W3132389716 cites W2159311956 @default.
• W3132389716 cites W2337855347 @default.
• W3132389716 cites W2587681779 @default.
• W3132389716 cites W2755443763 @default.
• W3132389716 cites W2807373052 @default.
• W3132389716 cites W2922208960 @default.
• W3132389716 cites W2924175085 @default.
• W3132389716 cites W2971660207 @default.
• W3132389716 cites W2980875266 @default.
• W3132389716 cites W2990647095 @default.
• W3132389716 cites W3093975822 @default.
• W3132389716 doi "https://doi.org/10.1093/neuonc/noab038" @default.
• W3132389716 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8408852" @default.
• W3132389716 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33599755" @default.
• W3132389716 hasPublicationYear "2021" @default.
• W3132389716 type Work @default.
• W3132389716 sameAs 3132389716 @default.
• W3132389716 citedByCount "8" @default.
• W3132389716 countsByYear W31323897162021 @default.
• W3132389716 countsByYear W31323897162022 @default.
• W3132389716 countsByYear W31323897162023 @default.
• W3132389716 crossrefType "journal-article" @default.
• W3132389716 hasAuthorship W3132389716A5000050947 @default.
• W3132389716 hasAuthorship W3132389716A5001497458 @default.
• W3132389716 hasAuthorship W3132389716A5014871240 @default.
• W3132389716 hasAuthorship W3132389716A5020712237 @default.
• W3132389716 hasAuthorship W3132389716A5021609838 @default.
• W3132389716 hasAuthorship W3132389716A5046132413 @default.
• W3132389716 hasAuthorship W3132389716A5046406895 @default.
• W3132389716 hasAuthorship W3132389716A5060316016 @default.
• W3132389716 hasAuthorship W3132389716A5070289110 @default.
• W3132389716 hasBestOaLocation W31323897161 @default.
• W3132389716 hasConcept C126322002 @default.
• W3132389716 hasConcept C126894567 @default.
• W3132389716 hasConcept C143998085 @default.
• W3132389716 hasConcept C207103383 @default.
• W3132389716 hasConcept C2776194525 @default.
• W3132389716 hasConcept C2778424827 @default.
• W3132389716 hasConcept C2989005 @default.
• W3132389716 hasConcept C44249647 @default.
• W3132389716 hasConcept C502942594 @default.
• W3132389716 hasConcept C50382708 @default.
• W3132389716 hasConcept C509974204 @default.
• W3132389716 hasConcept C535046627 @default.
• W3132389716 hasConcept C71924100 @default.
• W3132389716 hasConceptScore W3132389716C126322002 @default.
• W3132389716 hasConceptScore W3132389716C126894567 @default.
• W3132389716 hasConceptScore W3132389716C143998085 @default.
• W3132389716 hasConceptScore W3132389716C207103383 @default.
• W3132389716 hasConceptScore W3132389716C2776194525 @default.
• W3132389716 hasConceptScore W3132389716C2778424827 @default.
• W3132389716 hasConceptScore W3132389716C2989005 @default.
• W3132389716 hasConceptScore W3132389716C44249647 @default.
• W3132389716 hasConceptScore W3132389716C502942594 @default.
• W3132389716 hasConceptScore W3132389716C50382708 @default.
• W3132389716 hasConceptScore W3132389716C509974204 @default.
• W3132389716 hasConceptScore W3132389716C535046627 @default.
• W3132389716 hasConceptScore W3132389716C71924100 @default.
• W3132389716 hasFunder F4320332161 @default.
• W3132389716 hasIssue "9" @default.
• W3132389716 hasLocation W31323897161 @default.
• W3132389716 hasLocation W31323897162 @default.
• W3132389716 hasLocation W31323897163 @default.
• W3132389716 hasOpenAccess W3132389716 @default.
• W3132389716 hasPrimaryLocation W31323897161 @default.
• W3132389716 hasRelatedWork W1727188710 @default.
• W3132389716 hasRelatedWork W2119154902 @default.
• W3132389716 hasRelatedWork W2133235702 @default.
• W3132389716 hasRelatedWork W2135028155 @default.
• W3132389716 hasRelatedWork W2203903734 @default.
• W3132389716 hasRelatedWork W2343768426 @default.
• W3132389716 hasRelatedWork W2917746345 @default.

• next